Op-Eds

Tackling equity at Boston’s exam schools

August 5, 2019/by Jim Stergios

Melville readies students for rough seas ahead

July 31, 2019/by Jamie Gass

The Supreme Court Is Set To Decide Whether Religious Kids Are Allowed A Good Education

July 19, 2019/by Jamie Gass

Boston companies can partner with public universities to create fintech skills pipeline

July 12, 2019/by Eamon McCarthy Earls

Report: Rare Disease Patients Hurt by “One-Size-Fits-All” ICER Framework

June 26, 2019/by Editorial Staff

Denying students the opportunity to study classic works of literature leads to a culture of mediocrity

June 20, 2019/by Jamie Gass

More students, employers need to benefit from voc-tech schools’ winning formula

June 19, 2019/by Tom Birmingham

Putting a Price on Life: The Coming Fight Over Government Rationing of Medical Care

June 12, 2019/by Editorial Staff

The Mass. Pike is in for some massive disruption. Are we ready?

May 31, 2019/by Mary Connaughton

To Keep Our Republic, American Students Must Study The French Revolution

May 31, 2019/by Jamie Gass

Uber May Not Be Perfect, But Do We Want To Give The Transportation Revolution A Flat Tire?

May 16, 2019/by Jim Stergios

How Massachusetts Showed the Way on Education Reform

May 16, 2019/by Jamie Gass

Mass Pike rebuild shouldn’t impact Worcester commuters, but it will

May 3, 2019/by Mary Connaughton

Guglielmo Marconi and the importance of innovation and choice in education

May 1, 2019/by Jamie Gass

Here’s why Sarah Palin’s ‘death panels’ are now being debated in Massachusetts

April 25, 2019/by Editorial Staff

Issue Brief: Problems With The Institute of Clinical and Economic Review (ICER) and the QALY Methodology

April 23, 2019/by Editorial Staff

Commentary: Proposed Drug Price Caps Would Stall Advances in Health Care

April 23, 2019/by Editorial Staff

HHS Secretary Alex Azar doesn’t want drug access to become an equation

April 18, 2019/by Editorial Staff

Action on health care pricing transparency needed to stem rising costs

April 12, 2019/by Jim Stergios

The U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews

February 22, 2019/by Editorial Staff

Baker’s Orwellian drug pricing policy

February 3, 2019/by Editorial Staff